Loading...
XSTO
VICO
Market cap317mUSD
Jul 10, Last price  
12.76SEK
1D
-0.62%
1Q
27.98%
Jan 2017
-20.83%
IPO
141.89%
Name

Vicore Pharma Holding AB

Chart & Performance

D1W1MN
XSTO:VICO chart
P/E
—
P/S
797.50
EPS
—
Div Yield, %
—
Shrs. gr., 5y
34.62%
Rev. gr., 5y
-11.73%
Revenues
4m
-96.51%
3,3143,305,0001,571,000840,000852,000932,000508,00000000109,346,0003,817,000
Net income
-477m
L+183.14%
-3,158-1,603,00013,687,000-4,570,000-6,652,000-12,855,000-21,681,000-93,084,000-146,862,000-296,481,000-288,422,000-310,942,000-168,634,000-477,474,000
CFO
-374m
L+127.00%
-1,669-1,793,000-2,825,000-3,682,000-7,251,000-7,705,000-33,036,000-86,999,000-119,935,000-265,171,000-299,919,000-249,583,000-164,946,000-374,435,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Vicore Pharma Holding AB (publ), a Gothenburg, Sweden-based company, specializes in the discovery and advancement of therapies for rare lung conditions. Its core pipeline features VP01, an orally administered small molecule currently in Phase II clinical trials for indications such as interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19. The company is also progressing VP02, a novel formulation and delivery approach for an established immunomodulatory compound, which is in preclinical development for treating IPF. Vicore maintains strategic alliances, including a development cooperation with Emeriti Bio AB, a licensing arrangement with Nanologica AB (publ), and a collaboration with Alex Therapeutics AB focused on creating and clinically validating a digital therapeutic (DTx) built on the Alex DTx platform. Established in 2000, the company was formerly known as Mintage Scientific AB.
URL
https://vicorepharma.com/
IPO date
Dec 10, 2015
Employees
23
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT